2834 – Page 185 – China Stock Advice

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[Biostar Pharmaceuticals, Beginssembly of New Production Linereases overallpacity by $30 million annually and paves way for entrance into the Military Pharmaceutical Market XIANYANG, China, May 25, 2010 (Xinhua-PRNewswire-FirstCall) BSPM News Biostarmpleted Chinese Military Drugministration clinical trials for Zushima Analgesicrosolray (Zushima) in April through the Chinese No. 4 Military Medical University. Zushima is a traditional Chinese]

By info| 2016-02-07T17:23:04+00:00 May 25th, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: 0001418133, 2010-05-25, 2834, 8-K, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Beginssembly of New Production Linereases overallpacity

[Biostar Pharmaceuticals, Beginssembly of New Production Linereases overallpacity by $30 million annually and paves way for entrance into the Military Pharmaceutical Market XIANYANG, China, May 25, 2010 (Xinhua-PRNewswire-FirstCall) BSPM News Biostarmpleted Chinese Military Drugministration clinical trials for Zushima Analgesicrosolray (Zushima) in April through the Chinese No. 4 Military Medical University. Zushima is a traditional Chinese]

By info| 2016-02-07T17:23:59+00:00 May 25th, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: 0001418133, 2010-05-25, 2834, 8-K, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Unaudited First Quarter 2010 Financial Results - Conference call scheduled for Thursday, May 13, 2010 at 8:00 PM EDT Sinovac Biotech Ltd. ( Beijing May 13, 2010 NASDAQ: SVA), a leading China-based vaccine manufacturer , announc ed today its un audited financial results for the three-month period ended March 31, 2010. First Quarter 2010 Financial] [1 -32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]

By info| 2016-03-24T03:06:19+00:00 May 19th, 2010|Categories: Chinese Stocks, SEC Original, SVA|Tags: 0001084201, 2010-05-19, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Reports Unaudited First Quarter 2010 Financial Results

[Sinovac Reports Unaudited First Quarter 2010 Financial Results - Conference call scheduled for Thursday, May 13, 2010 at 8:00 PM EDT Sinovac Biotech Ltd. ( Beijing May 13, 2010 NASDAQ: SVA), a leading China-based vaccine manufacturer , announc ed today its un audited financial results for the three-month period ended March 31, 2010. First Quarter 2010 Financial] [1 -32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]

By info| 2016-03-24T03:08:05+00:00 May 19th, 2010|Categories: Chinese Stocks, SVA, Webplus ver|Tags: 0001084201, 2010-05-19, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)

[NEWS RELEASE Skystar Bio-Pharmaceutical Reports 27% Growth in Revenue From Continuing Operations in First Quarter Fiscal Year 2010 Gross Margin of 53%; $0.15 Diluted Earnings Per Share; Fiscal 2010 Top Line Guidance Increased to $45.5 Million to $47.5 Million XI’AN, CHINA – May 18, 2010 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), First Quarter 2009 Highligh ts]

By info| 2016-03-01T06:07:27+00:00 May 18th, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: 0001076939, 2010-05-18, 2834, 8-K, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: NEWS RELEASE Skystar Bio-Pharmaceutical Reports 27% Growth in

[NEWS RELEASE Skystar Bio-Pharmaceutical Reports 27% Growth in Revenue From Continuing Operations in First Quarter Fiscal Year 2010 Gross Margin of 53%; $0.15 Diluted Earnings Per Share; Fiscal 2010 Top Line Guidance Increased to $45.5 Million to $47.5 Million XI’AN, CHINA – May 18, 2010 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), First Quarter 2009 Highligh ts]

By info| 2016-03-01T06:08:15+00:00 May 18th, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: 0001076939, 2010-05-18, 2834, 8-K, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: (Original Filing)

[NEWS RELEASEystar Bio-Pharmaceutical Reports 27% Growth in Revenue Fromntinuing Operations in First Quarter Fiscal Year 2010 Gross Margin of 53%; $0.15 Diluted Earnings Per Share; Fiscal 2010 Top Line Guidancereased to $45.5 Million to $47.5 Million XIAN, CHINA May 18, 2010 -- -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"),]

By info| 2016-02-05T04:16:31+00:00 May 18th, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: 0001076939, 2010-05-18, 2834, 8-K, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: NEWS RELEASEystar Bio-Pharmaceutical Reports 27% Growth in Revenue

[NEWS RELEASEystar Bio-Pharmaceutical Reports 27% Growth in Revenue Fromntinuing Operations in First Quarter Fiscal Year 2010 Gross Margin of 53%; $0.15 Diluted Earnings Per Share; Fiscal 2010 Top Line Guidancereased to $45.5 Million to $47.5 Million XIAN, CHINA May 18, 2010 -- -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"),]

By info| 2016-02-05T04:17:03+00:00 May 18th, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: 0001076939, 2010-05-18, 2834, 8-K, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q: SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page Number

[SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page Number 3 PART I. FINANCIAL INFORMATION Item 1. Financial Statements (unaudited) F-1] [CERTIFICATION I, Weibing Lu , certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company ; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, , certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact nece ssary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION Weibing Lu (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer EX-32.1 5 v185379_ex32-1.htm] [CERTIFICATION (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Michael H. Lan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 v185379_ex32-2.htm]

By info| 2016-03-01T06:16:18+00:00 May 17th, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: 0001076939, 10-Q, 2010-05-17, 2834, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[BIOSTAR PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS XIANYANG, China, May 17, 2010 (Xinhua-PRNewswire-FirstCall) - Q1 2010 revenue increased 66.0% to $12.4 million - Q1 gross margins were 77.0%, a 1,270-basis point improvement - Q1 2010 Non-GAAP adjusted net income increased 32.1% to $2.4 million with adjusted EPS of $0.09 - Biostar reiterates guidance for 2010: Revenue expected to]

By info| 2016-03-03T14:24:38+00:00 May 17th, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: 0001418133, 2010-05-17, 2834, 8-K, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments